Tumorad-01 is a phase I/IIa first-in-human study in patients with advanced cancer with the primary objective of evaluating safety, tolerability, dosimetry and initial efficacy of 177Lu-SN201. The phase I part of the study is designed for up to 30 cancer patients and aims to, based on safety and biodistribution, identify a possible therapeutic dose for further testing in selected patient groups in the phase IIa part of the study.
"We are pleased to see that the first patient with advanced cancer has now been successfully dosed in this first in human study within the Tumorad program. With an open study design that allows for continuous data reporting, we expect initial data demonstrating the biodistribution and accumulation of 177Lu-SN201 in tumors in cancer patients early in the study. These data are of great importance as they can give an indication of the utility of the compound in cancer patients," says CEO
The study is initially run at a number of clinics in
Study details will be published at www.clinicaltrials.gov.
Clinical evidence of selective tumor accumulation of
The Tumorad-01 study is designed to enable early data demonstrating safety, biodistribution and accumulation of 177Lu-SN201 in tumors in cancer patients. With a favorable distribution of radiation to tumors compared to other organs, 177Lu-SN201 has good potential to become an effective drug against cancer.
© Modular Finance, source